Since the publication of the early in vitro experiments with tocopherol,2" I have published, with others, reports on the clinical use of what we have called an antithrombin test and on the use of tocopherol and calcium as prophylactic agents in postoperative thrombosis.8'" Since we originally had no concept of the course the clinical work would follow, certain statements which are contradictory appear in these earlier articles as they are read in chronological order. It is the purpose of this article to clarify certain of these statements and to attempt to define the phenomenon which we measure by the antithrombin test.
I have published, with others, reports on the clinical use of what we have called an antithrombin test and on the use of tocopherol and calcium as prophylactic agents in postoperative thrombosis.8'" Since we originally had no concept of the course the clinical work would follow, certain statements which are contradictory appear in these earlier articles as they are read in chronological order. It is the purpose of this article to clarify certain of these statements and to attempt to define the phenomenon which we measure by the antithrombin test. In the evaluation of any work, it seems reasonable that it should be broken down into its component parts and that these should be evaluated separately before the whole is accepted or discarded. Our clinical work on phlebothrombosis has consisted of three parts. One part is the evaluation of the antithrombin test as an indicator of a prethrombotic state. The second part concerns'the effect of alpha tocopherol and calcium on antithrombin levels. The third part concerns the effect of alpha tocopherol and calcium on the incidence of intravascular clotting. Our data will be considered from these three aspects.
Certain basic data must be mentioned before the antithrombin test which we have devised is described. In our first paper on the ability of alpha tocopherol to inhibit thrombin, the statement was made that "practically no antithrombic activity remains in the supernatant fluid" after precipitation of the disodium salt of alpha tocopherol (25 mg.) by 0.1 ml. of 1 per cent CaCl2. Subsequently we published studies on the use of calcium and tocopherol to increase the ability of plasma to inhibit thrombin. In our in vitro work in which we were dealing with thrombin in amounts of from 2 to 150 units, we found that the calcium salt of alpha tocopherol is only able to inhibit 0.06 units of thrombin. However, in dealing with plasma, we found that it requires only 0.06 units of thrombin to produce clotting in all normal plasmas. An amount of inhibitor which can be regarded as practically none in the first instance thus becomes of great significance when one is dealing with plasma.
It should be emphasized again that there is a 1 :1 relationship between the concentration of fibrinogen and the antithrombic activity of the sodium salts of alpha tocopherol. Thus it is necessary to add 5 mg. of the disodium salt of alpha tocopherol to plasma before a measurable increase in the ability of plasma to inhibit thrombin is noted. On the other hand, mere traces of the calcium salt of alpha tocopherol raise the level of plasma to maximum normal levels.
Further misunderstanding (which I did not anticipate) has arisen from an attempt by some observers to carry over the in vitro work to the in vivo interpretation of these phenomena. This is not justified. In working with the alpha globulin thrombin inhibitor we were able to identify a tocopherollike molecule. This compound was assayable by the Emmerie-Engle technique. It should be remembered that the phosphate salt of alpha tocopherol is not assayable by this technique, it being the=OH radical of the quinone portion of the molecule which is responsible for the anti-oxidant action of the molecule in this reaction.
We do believe that the antithrombic activity of this fraction is due to its tocopherol content, since we have tested other salts (alpha tocopherol sulphate and chroman, and coumarin phosphate)* and have found that the only effective thrombin inhibitors are those with the full tocopherol structure. These observations led us to conclude that it is the structure of the molecule, rather than any specific chemical reaction, which accounts for its activity, and to conclude further that if the molecule could be made watersoluble in the form of a lipo-protein, it would retain this activity.
This will mean, however, that assayable levels of alpha tocopherol will not appear in circulating blood following the administration of alpha tocopherol phosphate unless the tocopherol is hydrolyzed before or after venous blood is withdrawn. The former is apparently not the case.
The data do not justify the conclusion that alpha tocopherol phosphate is a normal constituent of blood or that the antithrombic effect of the administration of alpha tocopherol phosphate reproduces a normal physiological metabolic process. Epstein and Morgulis,' however, have published data on the efficacy of alpha tocopherol phosphate in treating nutritional muscular dystrophy in rabbits, which means that the avitaminosis responds to therapy with tocopherol phosphate.
Further confusion concerning our work has arisen from the fact that the antithrombin test is not entirely reliable when a commercial source of thrombin is used. In our original work we used 65 unit-ampules of thrombin, which were carefully assayed. Using this particular source of thrombin, we described a one-stage and a two-stage technique, the two tests correlating well. When, however, we began to use a commercial thrombin, which is the only source available to most investigators, we found that the onestage technique, which we had reported in two published articles, was un-*Supplied by Mr. Rudolph Frundt of the Warren-Teed Products Co. satisfactory and that the two tests no longer correlated, low values being obtained more frequently with the two-stage. Above 1: 16 the correlation was very good, but 1: 8 levels were seldom obtained with the one-stage technique, while they continued to occur when the two-stage technique was used. The difference between the two tests is fairly simple. In the one-stage technique, the clot is read after the thrombin is diluted and added to whole plasma. In the two-stage technique, the plasma is diluted, a constant amount of thrombin is added, the mixture is incubated, and fibrinogen is added to it before the clot is read. Since amounts of thrombin in the two tests are essentially equivalent, the fact that they do not correlate in low levels immediately raises the question whether we are actually measuring an antithrombin. For this reason, we are now proposing the name "prethrombotic index" for the test which we have described. The thrombin preparations, of course, contain various amounts of the factors necessary to convert prothrombin to thrombin since the technique of preparing thrombin consists of adsorption of prothrombin from plasma and subsequent conversion, by the addition of calcium, thromboplastin, and greater or lesser amounts of accelerator globulin. If the two tests correlated, it would be reasonable to assume that the thrombin is the substance responsible for the clot production. Since they do not, the question arises whether in the two-stage technique we are not measuring the ability of lesser amounts of thromboplastin, calcium, accelerator globulin, or thrombin to convert the prothrombin in diluted plasma. At the present time we are unable to define the exact nature of the test which we use, and we therefore feel that it would be better to call it a prethrombotic index and to emphasize that if the test is to be used for prediction of a prethrombotic stage, it must be done in two stages, as follows:
1. Place in a test tube 1.4 ml. of 1.85% solution of K2CrO4.
2. Add 10 ml. of blood as soon as it is withdrawn and mix well.
3. Centrifuge at 1,500 RPM for 10 minutes. e. Continue to dilute the plasma in the manner described until 10 tubes have been prepared. The dilution in the tenth tube is 1:512. 6. Add to each tube exactly 0.1 ml. of thrombin solution in distilled water. This thrombin is put up in ampoules of varying concentration. Exact amount in each ampoule (labelled 1000 units) can be determined by writing Eugene Loomis, Parke Davis Research Laboratory, Detroit. It is diluted so that each cubic centimeter contains 0.01 unit of thrombin. 7. Shake the tubes well, then incubate them in a water bath at 37.5°C.
8. Add to each tube 0.1 ml. of 3%o bovine fibrinogen (Armour and Co.) solution (in distilled water). The fibrinogen must be frozen and thawed. The profibrin which is precipitated by freezing is removed by centrifugation and discarded.
Only the clear supernatant is used. The solution is prepared by weight and contains 40-50% sodium citrate. 9. Incubate the tubes for another 60 minutes. 10. Observe each tube for the last trace of fibrin formation, recording the greatest dilution at which it ceases to occur. The fibrin frequently appears as a fine precipitate occurring in decreasing amounts. In normal plasma, fibrin formation ceases to occur when the plasma dilution is between 1:32 and 1:128.
Evaluation of results The data accumulated over the past two years, we believe, strongly suggest that the test which we have devised actually is of value in predicting thrombosis. Thus in 246 cases that were studied as controls, there occurred 23 cases of thrombosis or embolism, with 5 embolic deaths. All 5 patients showed a 1: 8 level on or shortly before the day of death. In one non-fatal instance of embolism, the 1: 8 level was not obtained, this being the only case in our control series in which a 1: 8 level was not present when either thrombosis or symptoms of emboli developed. Thrombosis was diagnosed clinically in 16 cases in the series. All of these patients were submitted to venous ligation following the diagnosis and in 8 instances, clots were found at the time of the ligation. The diagnosis of phlebothrombosis in these cases was made on the basis of any two of three physical findings, namely, calf tenderness, unilateral edema, or dilation of the peripheral veins. Patients showing only one of this triad were not considered as having phlebothrombosis in this particular portion of study.
Later we broadened these criteria. In the total series of 246 cases, a number of 1:8 levels were obtained in patients who did not develop clinical phlebothrombosis by our criteria of diagnosis. When the prothrombin times were analyzed in relation to the occurrence of 1: 8 levels, it was found that only those patients who had normal or near-normal prothrombin times, develop the clinical syndrome.
Our studies indicated that this differential in prothrombin times could not be picked up if rabbit brain thromboplastin was used. When we used thromboplastin from this source, which gives a very rapid prothrombin time, a large percentage of the measurements were found to be normal or 100 per cent. When, on the other hand, a lung thromboplastin was used, which gave a normal control prothrombin time of approximately 16 seconds, it was found that many of the patients showed prothrombin times of over 20 seconds.
In the group of patients showing 1: 8 levels and prothrombin times longer than 20 seconds, there was only one instance of thrombosis, a fatal case of cerebral thrombosis confirmed at autopsy. On the other hand, in the group of patients showing 1: 8 levels and having prothrombin times shorter than 20 seconds on the same day, 23 developed phlebothrombosis. There was no particular day, in terms of postoperative days, on which the low levels occurred, but it was observed that they usually preceded the occurrence of clinical symptoms of phlebothrombosis by 6 to 72 hours. Frequently, the clinical syndrome had developed between the time the blood was drawn, the levels determined, and the patients checked on the wards for possible symptoms.
For this chronologic reason the prethrombotic index alone is not entirely practical. Therapy cannot always be instituted before the disease occurs. The test did, however, help us in this particular group of patients in that we were able to ligate their veins perhaps somewhat earlier than would have been possible had we not had information indicating the possibility of thrombosis.
It must further be emphasized that this test must be run every day, including Sunday, since the omission of even one day could mean that the low level on that particular patient might be missed and the prethrombotic state not recognized.
Our experiences with this test have thus led us to place considerable faith in it for predicting the occurrence of thrombosis in association with a low prethrombotic index.
Interpretation of the effect of tocopherol and calcium on the incidence of low prethrombotic index level The next question of interpretation is concerned with the effect of alpha tocopherol and calcium administration on the prevention of low prethrombotic index levels. Our therapy consists in the administration of alpha tocopherol phosphate in doses of 100 mg. every 8 hours until the patient can take oral medication. After this time, 200 iu of alpha tocopherol acetate are given daily by mouth. In addition, 10 cc. of calcium gluconate are given every 24 hours. Medication is begun immediately after operation.
In 457 patients treated by this routine, we have found only 15 with 1: 8 levels. Statistically, no further comment seems needed. It is obvious that the administration of tocopherol and calcium, routinely, to postoperative patients results in a marked reduction of the incidence of low prethrombotic index levels. The natural corollary is that if we believe the prethrombotic index to be an efficient method of predicting thrombosis, and if we can maintain the prethrombotic index above that certain low level which is associated with thrombosis, then we should reduce the incidence of thrombosis.
This brings us to the third aspect of our work, namely, the effect of tocopherol and calcium on the incidence of thrombosis. To date we have treated only 457 patients. In evaluating the incidence of thrombosis in so small a group, it is impossible to say statistically that we have influenced the incidence of the disease because of the great variations which are seen from year to year. Our data show that we have had only 15 with 1: 8 levels and that these have been associated with 5 phlebothromboses, and with two pulmonary emboli. At the present time we consider a patient to have phlebothrombosis if he presents only one of the criteria which we use for diagnosis. That is, if a patient has only edema, or dilated peripheral veins, or calf tenderness, vein ligation is performed and he is considered to have had a phlebothrombosis. Indeed, at the present time it is our tendency to perform venous ligation on all 1: 8 levels if they have any complaint at all referable to the leg. Any conclusion, however, concerning the effect of tocopherol and calcium on the incidence of thrombosis must await a larger series of cases either from our own clinic or from other sources. Table 1 shows the type of case we have used in our study as well as the relative occurrence of thrombosis and embolism in 246 control and 395 treated cases. Patients submitted to sympathectomy and amputation have only recently been treated. They were added because in the year ending July 1, 1950 there was a significant number (5 cases) of emboli in these groups, although the incidence in other relatively minor operative groups remained the same.
We have been criticized in some quarters for discontinuing our control group, but we believe we are no longer justified in omitting prophylactic therapy in any patient who might develop thrombo-embolism after operation. The last one hundred controls and the first one hundred treated patients were seen simultaneously. The incidence of fatal emboli in patients with a 1: 8 level who had no peripheral sign of thrombosis was 2 per cent in our series, which was high enough to make us think that therapy was needed in all instances of possible thrombo-embolism. The risk of Dicumarol is too great to justify its use on surgical wards, particularly on wards where control and accurate following of prothrombin times is impossible. Moreover, even admitting the practicality of the routine use of anticoagulants during the postoperative period, such a group would not serve as a control on the incidence of thrombosis and embolism. It would merely permit comparison with the effectiveness of tocopherol and calcium. Since we know something of the dangers of routine Dicumarol prophylaxis, we did not feel that the use of such a group would add significance to our studies or reduce the overall mortality significantly. For these reasons, we now chose to compile our data in terms of a large group of patients, all of whom receive tocopherol and calcium prophylactically.
Summary Studies have shown that antithrombic activity of the calcium salt of alpha tocopherol is significant in terms of variations in the level of the prethrombotic index.
A low level ( 1: 8) as measured by the prethrombotic index is associated with a high incidence of thrombosis if, when this level is obtained, the prothrombin time of the patient is at or near normal.
The administration of tocopherol and calcium in prescribed amounts and by prescribed routes is associated with a marked reduction in the incidence of low prethrombotic index levels.
It is conceivable, though not yet proved statistically, that the administration of alpha tocopherol and calcium will reduce the incidence of postoperative phlebothrombosis and pulmonary embolism.
